Literature DB >> 26276360

Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.

Arife Ulas1, Ahmet Bilici2, Ayse Durnali3, Saadet Tokluoglu3, Sema Akinci4, Kamile Silay5, Berna Oksuzoglu3, Necati Alkis3.   

Abstract

Skeletal-related events (SREs) for nonsmall cell lung cancer (NSCLC) patients with bone metastasis lead to serious morbidity. The aim of this study was to determine risk factors for SREs in NSCLC patients with bone metastasis and the factors influencing SRE-free survival and overall survival (OS). From 2000 to 2012, we evaluated retrospectively 835 NSCLC patients. Three hundred and thirty-five of them with bone metastasis were included in the study. SREs and the other prognostic factors were evaluated by univariate and multivariate analysis for SRE-free survival and OS. SREs were detected in 244 patients (72.8 %). The most common SREs were the need for radiotherapy (43.2 %) and malignant hypercalcemia (17.6 %). The median time to first SRE was 3.5 months at the median follow-up of 17 months. A multivariate analysis showed that the presence of bone metastasis at diagnosis (p < 0.001), the number of bone metastasis (p = 0.001), baseline hypercalcemia (p = 0.004), and the presence of palliative radiotherapy (p = 0.04) were independent prognostic factors for SRE-free survival. A logistic regression analysis identified that the presence of bone metastasis at diagnosis [odds ratio (OR), 12.6], number of bone metastasis (OR, 3.05), and baseline hypercalcemia (OR, 0.33) were found to be predictive factors in the developing of SRE. The median OS time for patients with SRE was worse than that for patients without SRE (7 vs 12 months, respectively). For OS, male gender, ECOG performance status (PS), high lactate dehydrogenase (LDH) level, hypoalbuminemia, the presence of bone metastasis at diagnosis, the number of bone metastasis, the presence of SREs, the presence of bisphosphonate therapy, and palliative radiotherapy were independent prognostic indicators for OS by the multivariate analysis. Our results indicated that the frequency of SREs was high and the presence of bone metastasis at the time of diagnosis, baseline hypercalcemia, and multiple bone metastases were significant factors predicting the occurrence of SREs. If bone metastases diagnose earlier, treatments for the prevention of SREs may be initiated earlier; thus, the deterioration of quality of life may be preserved.

Entities:  

Keywords:  Bone metastases; Nonsmall cell lung cancer; SRE-free survival; Skeletal-free events

Mesh:

Year:  2015        PMID: 26276360     DOI: 10.1007/s13277-015-3907-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

Review 1.  Mechanisms of bone metastasis.

Authors:  G David Roodman
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

2.  A meta-analysis of the effects of cigarette smoking on bone mineral density.

Authors:  K D Ward; R C Klesges
Journal:  Calcif Tissue Int       Date:  2001-05       Impact factor: 4.333

3.  [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].

Authors:  Xiao-ye Hu; Qing-feng Zou; Chuan Jin; Wei-dong Li; Wen-sheng Chen; Lei Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2010-06

4.  Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.

Authors:  Hyun-Mi Bae; Se-Hoon Lee; Tae Min Kim; Dong-Wan Kim; Seok-Chul Yang; Hong Gyun Wu; Young Whan Kim; Dae Seog Heo
Journal:  Lung Cancer       Date:  2012-06-04       Impact factor: 5.705

5.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

6.  Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.

Authors:  Lee S Rosen; David Gordon; N Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; Maciej Krzakowski; Marek Pawlicki; Paul De Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John Seaman
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

7.  Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients.

Authors:  D Ferrigno; G Buccheri
Journal:  Monaldi Arch Chest Dis       Date:  2003 Jul-Sep

8.  Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.

Authors:  Nobuyuki Katakami; Hiroshi Kunikane; Koji Takeda; Koichi Takayama; Toshiyuki Sawa; Hiroshi Saito; Masao Harada; Soichiro Yokota; Kiyoshi Ando; Yuko Saito; Isao Yokota; Yasuo Ohashi; Kenji Eguchi
Journal:  J Thorac Oncol       Date:  2014-02       Impact factor: 15.609

Review 9.  Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.

Authors:  Syed H Jafri; Runhua Shi; Glenn Mills
Journal:  BMC Cancer       Date:  2013-03-27       Impact factor: 4.430

10.  Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.

Authors:  M I Koukourakis; A Giatromanolaki; E Sivridis; G Bougioukas; V Didilis; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

View more
  14 in total

1.  Prognostic factors in patients with skeletal-related events at non-small-cell lung cancer diagnosis.

Authors:  Hiroyuki Tominaga; Takao Setoguchi; Hirofumi Shimada; Satoshi Nagano; Hiromi Sasaki; Yasuhiro Ishidou; Masami Sato; Keiko Mizuno; Hiromasa Inoue; Setsuro Komiya
Journal:  Mol Clin Oncol       Date:  2017-08-25

2.  Risk factors for same-admission mortality after pathologic fracture secondary to metastatic cancer.

Authors:  Nicole K Behnke; Dustin K Baker; Shin Xu; Thomas E Niemeier; Shawna L Watson; Brent A Ponce
Journal:  Support Care Cancer       Date:  2016-10-04       Impact factor: 3.603

3.  Prognostic score for life expectancy evaluation of lung cancer patients after bone metastasis.

Authors:  Dumnoensun Pruksakorn; Areerak Phanphaisarn; Jongkolnee Settakorn; Urarat Arpornchayanon; Apichat Tantraworasin; Parunya Chaiyawat; Jeerawan Klangjorhor; Pimpisa Teeyakasem
Journal:  J Bone Oncol       Date:  2017-11-03       Impact factor: 4.072

4.  Risk factors for bone metastasis in patients with primary lung cancer: A systematic review.

Authors:  Yujie Niu; Yiting Lin; Hailin Pang; Weiwei Shen; Lili Liu; Helong Zhang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

5.  Clinical features and prognostic factors in patients with bone metastases from non-small cell lung cancer.

Authors:  Xiao-Tian Wu; Jian-Wei Zhou; Long-Ci Pan; Ting Ge
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

6.  A novel risk stratification for predicting prognosis of colorectal cancer patients with bone metastasis.

Authors:  Xiaolong Ma; Xu Guan; Chenxi Ma; Jichuan Quan; Zhixun Zhao; Haipeng Chen; Haiyang Huang; Ran Wei; Zheng Liu; Zheng Jiang; Yinggang Chen; Xishan Wang
Journal:  J Gastrointest Oncol       Date:  2021-06

7.  Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer - A retrospective analysis.

Authors:  Pengyu Kong; Jinglong Yan; Donghui Liu; Ye Ji; Yufu Wang; Jinpeng Zhuang; Jincai Wang; Xiaowei Hu; Xiaolong Yue
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 8.  Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management.

Authors:  Barbara Altieri; Carla Di Dato; Chiara Martini; Concetta Sciammarella; Antonella Di Sarno; Annamaria Colao; Antongiulio Faggiano
Journal:  Cancers (Basel)       Date:  2019-09-08       Impact factor: 6.639

9.  A prognostic index model to individually predict clinical outcomes for colorectal cancer with synchronous bone metastasis.

Authors:  Xu Guan; Chen-Xi Ma; Ji-Chuan Quan; Zhi-Xun Zhao; Hai-Peng Chen; Peng Sun; Song Wang; Zhao Lu; Xiao-Long Ma; Zheng Liu; Zheng Jiang; Xi-Shan Wang
Journal:  J Cancer       Date:  2020-05-11       Impact factor: 4.207

Review 10.  Olecranon metastases from primary lung cancer: case report and review of the literature.

Authors:  Leyi Cai; Shuangxia Dong; Hua Chen
Journal:  J Int Med Res       Date:  2019-09-23       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.